These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24214898)

  • 1. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
    Raykov Z; Grekova SP; Bour G; Lehn JM; Giese NA; Nicolau C; Aprahamian M
    Int J Cancer; 2014 Jun; 134(11):2572-82. PubMed ID: 24214898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypoxic Potentiation of Standard Therapy for Experimental Colorectal Liver Metastasis through Myo-Inositol Trispyrophosphate.
    Limani P; Linecker M; Kachaylo E; Tschuor C; Kron P; Schlegel A; Ungethuem U; Jang JH; Georgiopoulou S; Nicolau C; Lehn JM; Graf R; Humar B; Clavien PA
    Clin Cancer Res; 2016 Dec; 22(23):5887-5897. PubMed ID: 27489288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1α suppression and eradication of early hepatoma tumors in rats.
    Aprahamian M; Bour G; Akladios CY; Fylaktakidou K; Greferath R; Soler L; Marescaux J; Egly JM; Lehn JM; Nicolau C
    Chembiochem; 2011 Mar; 12(5):777-83. PubMed ID: 21370375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
    Suzuki K; Aiura K; Matsuda S; Itano O; Takeuchi O; Umezawa K; Kitagawa Y
    Clin Exp Metastasis; 2013 Apr; 30(4):381-92. PubMed ID: 23111540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes.
    Kieda C; Greferath R; Crola da Silva C; Fylaktakidou KC; Lehn JM; Nicolau C
    Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15576-81. PubMed ID: 17028170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors.
    Schneider MA; Linecker M; Fritsch R; Muehlematter UJ; Stocker D; Pestalozzi B; Samaras P; Jetter A; Kron P; Petrowsky H; Nicolau C; Lehn JM; Humar B; Graf R; Clavien PA; Limani P
    Nat Commun; 2021 Jun; 12(1):3807. PubMed ID: 34155211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
    Zhao M; Tominaga Y; Ohuchida K; Mizumoto K; Cui L; Kozono S; Fujita H; Maeyama R; Toma H; Tanaka M
    Cancer Sci; 2012 Jan; 103(1):58-66. PubMed ID: 21954965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour angiogenesis normalized by myo-inositol trispyrophosphate alleviates hypoxia in the microenvironment and promotes antitumor immune response.
    El Hafny-Rahbi B; Brodaczewska K; Collet G; Majewska A; Klimkiewicz K; Delalande A; Grillon C; Kieda C
    J Cell Mol Med; 2021 Apr; 25(7):3284-3299. PubMed ID: 33624446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
    Bruns CJ; Shrader M; Harbison MT; Portera C; Solorzano CC; Jauch KW; Hicklin DJ; Radinsky R; Ellis LM
    Int J Cancer; 2002 Nov; 102(2):101-8. PubMed ID: 12385004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable tumor vessel normalization with pO₂ increase and endothelial PTEN activation by inositol trispyrophosphate brings novel tumor treatment.
    Kieda C; El Hafny-Rahbi B; Collet G; Lamerant-Fayel N; Grillon C; Guichard A; Dulak J; Jozkowicz A; Kotlinowski J; Fylaktakidou KC; Vidal A; Auzeloux P; Miot-Noirault E; Beloeil JC; Lehn JM; Nicolau C
    J Mol Med (Berl); 2013 Jul; 91(7):883-99. PubMed ID: 23471434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
    Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
    BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
    Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
    Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
    Hotz B; Backer MV; Backer JM; Buhr HJ; Hotz HG
    Neoplasia; 2010 Oct; 12(10):797-806. PubMed ID: 20927318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of OXY111A, a novel hypoxia-modifier as a potential antitumor agent in patients with hepato-pancreato-biliary neoplasms - Protocol of a first Ib/IIa clinical trial.
    Limani P; Linecker M; Kron P; Samaras P; Pestalozzi B; Stupp R; Jetter A; Dutkowski P; Müllhaupt B; Schlegel A; Nicolau C; Lehn JM; Petrowsky H; Humar B; Graf R; Clavien PA
    BMC Cancer; 2016 Oct; 16(1):812. PubMed ID: 27756258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of reactive oxygen species by antioxidants suppresses hypoxia-induced epithelial-mesenchymal transition and metastasis of pancreatic cancer cells.
    Shimojo Y; Akimoto M; Hisanaga T; Tanaka T; Tajima Y; Honma Y; Takenaga K
    Clin Exp Metastasis; 2013 Feb; 30(2):143-54. PubMed ID: 22833345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of myo-inositol trispyrophosphate (ITPP) on tumour oxygenation and response to irradiation in rodent tumour models.
    Tran LB; Cao-Pham TT; Jordan BF; Deschoemaeker S; Heyerick A; Gallez B
    J Cell Mol Med; 2019 Mar; 23(3):1908-1916. PubMed ID: 30575283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.
    Kozono S; Ohuchida K; Eguchi D; Ikenaga N; Fujiwara K; Cui L; Mizumoto K; Tanaka M
    Cancer Res; 2013 Apr; 73(7):2345-56. PubMed ID: 23348422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
    Zhao T; Ren H; Jia L; Chen J; Xin W; Yan F; Li J; Wang X; Gao S; Qian D; Huang C; Hao J
    Oncotarget; 2015 Feb; 6(4):2250-62. PubMed ID: 25544770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.